Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alzamend Neuro's share price for the quarter that ended in Jan. 2024 was $0.86. Alzamend Neuro's Shares Outstanding (EOP) for the quarter that ended in Jan. 2024 was 6.62 Mil. Therefore, Alzamend Neuro's market cap for the quarter that ended in Jan. 2024 was $5.69 Mil.
Alzamend Neuro's quarterly market cap
declined
from Jul. 2023 ($43.91 Mil) to Oct. 2023 ($11.33 Mil) and
declined
from Oct. 2023 ($11.33 Mil) to Jan. 2024 ($5.69 Mil).
Alzamend Neuro's annual market cap
increased
from Apr. 2021 ($0.00 Mil) to Apr. 2022 ($97.39 Mil) but then
declined
from Apr. 2022 ($97.39 Mil) to Apr. 2023 ($53.06 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alzamend Neuro's Enterprise Value for Today is $4.70 Mil.
Alzamend Neuro Market Cap Historical Data
The historical data trend for Alzamend Neuro's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alzamend Neuro's Market Cap
For the Biotechnology subindustry, Alzamend Neuro's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Market Cap distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's Market Cap falls into.
Alzamend Neuro Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alzamend Neuro's Market Cap for the fiscal year that ended in Apr. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (NAS:ALZN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alzamend Neuro Market Cap Related Terms
Thank you for viewing the detailed overview of Alzamend Neuro's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Alzamend Neuro (Alzamend Neuro) Business Description
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALZN has been successfully added to your 